Yes — hepatitis C is curable for almost everyone. A short, all-oral course of direct-acting antiviral (DAA) pills, taken for roughly two to three months, clears the virus in more than 95% of people, and that cure is durable for years afterward CDC. There's no shot needed, and most people have no side effects worth mentioning.
most unaware
8–12 weeks of pills
| Item | Value |
|---|---|
| Acute reports | ~5,000/yr |
| Living with chronic HCV | ~2.4 million — most unaware |
| Cured by DAAs | >95% — 8–12 weeks of pills |
| Vaccine | none |
The essentials: what "cure" actually means
Hepatitis C is a liver disease caused by the hepatitis C virus (HCV), which spreads when blood from an infected person enters another person's bloodstream. The first six months after infection is called acute hepatitis C; most people who don't clear it on their own go on to develop a chronic, lifelong infection. This is the key difference from hepatitis B, which is managed but not cured.
A "cure" here has a precise meaning. Clinicians call it a sustained virologic response: HCV RNA stays undetectable in your blood months after you finish the pills. Modern DAA therapy reaches that in more than 95% of people, usually in an 8-to-12-week course, and it holds — the virus stays gone in over 99% of people followed five years CDC. Curing the infection stops ongoing liver damage and lowers the long-term risk of hepatitis c and cirrhosis.
The scale of the problem is larger than the official case counts suggest. Acute hepatitis C reports run around 5,000 a year, but that vastly undercounts the roughly 2.4 million Americans living with chronic HCV, most of whom don't know they're infected CDC AtlasPlus. Because the disease is usually silent, the diagnosis often comes from a routine screen before anyone feels sick.
Symptoms — and why "none" is the most common one
Most hepatitis C infections cause no symptoms at all. When acute symptoms do appear, jaundice (yellowing of the skin and the whites of the eyes, from a backup of bilirubin the inflamed liver can't process) shows up in only about 20–30% of people, and nonspecific symptoms — fatigue, poor appetite, abdominal pain, dark urine — in roughly 10–20%. Chronic hepatitis C is even quieter, often causing no specific symptoms for 20 years or more while it scars the liver.
Screening matters more than watching for symptoms. By the time obvious symptoms appear, the liver may already be significantly damaged. For a fuller breakdown of what does and doesn't show up, see hepatitis c symptoms in men and women.
Testing: how hepatitis C is diagnosed
Testing is a two-step process. It starts with an HCV antibody test, which detects whether your immune system has ever responded to the virus. If that's positive, the lab automatically runs a nucleic acid test (NAT) for HCV RNA on the same sample to confirm whether you have a current, active infection, because antibodies stay positive for life even after a past infection clears. A reactive antibody with a negative RNA means the virus is gone; a reactive antibody with a positive RNA means you're infected now CDC.
The CDC recommends screening all adults 18 and older at least once, and screening all pregnant people during each pregnancy. The USPSTF gives one-time screening for adults aged 18–79 a Grade B recommendation, which means most insurance covers it without a copay USPSTF. In practice, this is a simple blood draw with results usually back in a few days, and it's free or low-cost at health departments, Planned Parenthood, and Title X clinics. You can start with a hepatitis c test or arrange to get tested alongside other screening.
Timing matters after a possible exposure. Antibodies and viral RNA take time to become detectable, so a too-early test can miss a real infection. If you've had a recent exposure, check when to test after exposure before you book.
Treatment: which DAA regimen, and what to expect
Treatment is an 8-to-12-week course of oral direct-acting antivirals — pills that block specific proteins the virus needs to copy itself. There's no injection, no interferon, and for most people very little in the way of side effects. The simplified regimens used today are glecaprevir/pibrentasvir (Mavyret) taken for 8 weeks, or sofosbuvir/velpatasvir (Epclusa) taken for 12 weeks. Both are pangenotypic, meaning they work across the different HCV genotypes, so genotype testing is often no longer required before starting AASLD/IDSA.
Specialist guidance now recommends treating essentially everyone with hepatitis C, not just people with advanced liver disease, because curing the infection early prevents the damage. Here's how the two simplified regimens compare for a first-time, treatment-naïve patient without cirrhosis:
| Regimen | Typical course | Genotype coverage | Cure rate |
|---|---|---|---|
| Glecaprevir/pibrentasvir (Mavyret) | 8 weeks | Pangenotypic (all) | More than 95% |
| Sofosbuvir/velpatasvir (Epclusa) | 12 weeks | Pangenotypic (all) | More than 95% |
Take every dose, and finish the full course even after you feel fine. Stopping early is the main reason a cure fails and can encourage resistance. Your clinician will check an HCV RNA test after you finish to confirm the virus is gone. If cost is the barrier, ask about patient-assistance programs from the manufacturers and Medicaid coverage; these regimens are widely covered, and many people pay little out of pocket.
Prevention: no vaccine, but real protection
There is no vaccine for hepatitis C, so prevention is about avoiding blood-to-blood contact CDC. The highest-yield steps:
- Don't share needles, syringes, or any drug-injection equipment — this is the leading route of transmission in the U.S.
- Don't share personal items that can carry traces of blood, like razors, toothbrushes, or nail clippers.
- Use syringe services programs, which provide clean equipment and lower transmission in the community.
- Use condoms during higher-risk sex; sexual transmission is less common than with most STIs but rises with certain practices.
- Get screened — routine testing catches the infections that have no symptoms, which is most of them.
A cure doesn't make you immune. Hepatitis C antibodies stay positive for life, so reinfection is possible if you're re-exposed, and only an RNA (viral) test can detect a new infection. Anyone with ongoing risk should retest annually.
When to see a clinician
Get tested if you've never been screened; that one-time test is recommended for nearly every adult regardless of how you feel. See a clinician sooner if you've ever injected drugs, received a blood transfusion or organ transplant before widespread blood screening, had a needlestick at work, or have a known exposure. If you're pregnant, ask for screening at each pregnancy. And if a previous test came back positive but you never started treatment, it's worth a fresh visit — the pills available now are far simpler and more effective than older options.